The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids

Pain

Volumn 142, Issue 1-2, 2009, Pages 94-100

  Rezende, Rafael Machado ^a   Reis, Webster Glayser Pimenta dos ^a   Duarte, Igor Dimitri Gama ^a   Lima, Patrícia Paiva ^a   Bakhle, Yeshwant S ^b   Francischi, Janetti Nogueira de ^a  

^a Institute of Biological Sciences   (Brazil)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Celecoxib; Central nervous system; Endogenous opioids; Hypoalgesia

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; BESTATIN; CARRAGEENAN; CELECOXIB; INDOMETACIN; MORPHINE; NALTREXONE; OPIATE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; HYPERALGESIA; HYPOALGESIA; INFLAMMATION; MALE; MECHANICAL STIMULATION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; IMMUNOLOGIC FACTORS; INFLAMMATION; INJECTIONS, INTRAVENTRICULAR; LEUCINE; MALE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PYRAZOLES; RATS; REACTION TIME; SULFONAMIDES; TIME FACTORS;

EID: 60049087068     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.12.005     Document Type: Article

References (32)

1. Baliki M., Al-Amin H.A., Atweh S.F., Jaber M., Hawwa N., Jabbur S.J., et al. Attenuation of neuropathic manifestations by local block of the activities of the ventrolateral orbito-frontal area in the rat. Neuroscience 120 (2003) 1093-1094
2. Beiche F., Scheuerer S., Brune K., Geisslinger G., and Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390 (1996) 165-169
3. Bingham S., Beswick P.J., Bountra C., Brown T., Campbell I.B., Chessell I.P., et al. The cyclooxygenase-2 inhibitor GW406381 X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl] -pyrazolo[1,5- b ]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther 312 (2005) 1161-1169
4. Breder C.D., Dewitt D., and Kraig R.P. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 355 (1995) 296-315
5. Burian M., and Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 107 (2005) 139-154
6. Ciceri P., Zhang Y., Shaffer A.F., Leahy K.M., Woerner M.B., Smith W.G., et al. Pharmacology of celecoxib in rat brain after kainate administration. J Pharmacol Exp Ther 302 (2002) 846-852
7. Dembo G., Park S.B., and Kharash E.D. Central nervous system concentrations of cyclooxygenase-2 inhibitors. Anesthesiology 102 (2005) 409-415
8. Di Rosa M. Biological properties of the carrageenan. J Pharm Pharmacol 24 (1972) 89-102
9. Ferreira S.H. Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol 240 (1972) 200-203
10. França D.S., Ferreira-Alves D.L., Duarte I.D., Ribeiro M.C., Rezende R.M., Bakhle Y.S., et al. Endogenous opioids mediate the hypoalgesia induced by inhibitors of cyclooxygenase-2 in rat paws treated with carrageenan. Neuropharmacology 51 (2006) 37-43
11. Francischi J.N., Chaves C.T., Moura A.C.L., Lima A.S., Rocha O.A., Ferreira-Alves D.L., et al. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 137 (2002) 837-844
12. Grosch S., Maier T.J., Schiffmann S., and Geisslinger G. Cycloxygenase-2 (COX-2)-Independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98 (2006) 736-747
13. 2 synthase-1. J Biol Chem 279 (2004) 24866-24872
14. Herrero J.F., and Headley P.M. Reversal by naloxone of the spinal antinociceptive actions of a systemically administered NSAID. Brit J Pharmacol 118 (1996) 968-972
15. Hétu P.O., and Riendeau D. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem J 391 Pt. 3 (2005) 561-566
16. Michel R.E., Holt J.C., and Domer F.R. Ketorolac causes the release of methionine-enkephalin in rats. Res Comm Mol Pathol Pharmacol 91 (1996) 249-252
17. Okumura T., Murata Y., Hizue M., Matsuura T., Naganeo R., Kanai Y., et al. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor. Eur J Pharmacol 539 (2006) 125-130
18. Parsons C.G., and Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for activation by enkephalin-like opioid peptides after cold water swim stress. J Pharmacol Exp Ther 255 (1990) 795-802
19. Paulson S.K., Zhang J.Y., Breau A.P., Hribar J.D., Liu N.W.K., Jessen S.M., et al. Pharmacokinetics, tissue distribution, metabolism and excretion of celecoxib in rats. Drug Metab Dispos 28 (2000) 514-521
20. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd ed. (1986), Academic Press, Sidney, Australia
21. Penning T.B., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., et al. Synthesis and biological evaluation of the 1,5-Diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5- (4-Methylphenyl)-3- (trifluoromethyl)- 1 H -pyrazol-1-y1] benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 40 (1997) 1347-1365
22. Pereira L.S., Ferreira-Alves D.L., Resende M.A., Romualdo M.A., Dos Reis W.G.P., Lopes M.T., et al. Reduced production of hyperalgesic substances by mononuclear cells from aged rats incubated with carrageenan: role of interleukin-2 and prostaglandins. Inflamm Res 52 (2003) 119-125
23. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissues. Arch Int Pharmacodyn Therap 111 (1957) 409-419
24. Saadé N.E., Al-Amin H., Chalouhi S., Baki S.A., Jabbur S.J., and Atweh S.F. Spinal pathways involved in supraspinal modulation of neuropathic manifestations in rats. Pain 126 (2006) 280-293
25. Saadé N.E., and Jabbur S.J. Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog Neurobiol 86 (2008) 22-47
26. Scornik O.A., and Botbol V. Bestatin as an experimental tool in mammals. Curr Drug Metab 2 (2001) 67-85
27. Smith C.J., Zhang Y., Kobolt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., et al. Pharmacological analysis of cyclooxygnease-1 in inflammation. Proc Natl Acad Sci USA 95 (1998) 13313-13318
28. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat New Biol 231 (1971) 232-235
29. Vinegar R., Truax J.F., Selph J.L., Johnston P.R., Venable A.L., and McKenzie K.K. Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed Proc 46 (1987) 118-126
30. Wang W., Kardosh A., Su Y.S., Schonthal A.H., and Chen T.C. Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. Neurosurg Focus 21 (2006) E14
31. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 6 (1983) 109-110
32. Zöllner C., Shaquira M.A., Bopaiah C.P., Mousa S., Stein C., and Schäfer M. Painful inflammation-induced increase in (-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol 64 (2003) 202-210